Has Chemo Pharma Lab declared dividend?

No Dividend History Available

Who are the peers of the Chemo Pharma Lab?

Chemo Pharma Lab's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Phaarmasia, Desh Rakshak, Parmax Pharma, and Saroja Pharma In. Notably, Desh Rakshak has the highest 1-year return at 422.50%, while Phaarmasia has the lowest at -24.74%, with Chemo Pharma Lab's return at 95.75%.

Peers: The peers of Chemo Pharma Lab are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Phaarmasia, Desh Rakshak, Parmax Pharma, and Saroja Pharma In.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Saroja Pharma In, while Good management risk is found at Divi's Lab., Torrent Pharma, and the rest. Growth is excellent at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is noted at Divi's Lab., Torrent Pharma, Phaarmasia, Desh Rakshak, Parmax Pharma, and the rest. Excellent capital structure is seen at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Good capital structure is found at Torrent Pharma, and Below Average capital structure is noted at Divi's Lab., Phaarmasia, Desh Rakshak, Parmax Pharma, and Saroja Pharma In.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Desh Rakshak at 422.50%, while the peer with the lowest is Phaarmasia at -24.74%. Chemo Pharma Lab's own 1-year return is 95.75%, which is significantly higher than Phaarmasia's but lower than Desh Rakshak's. Additionally, Phaarmasia and Parmax Pharma have negative six-month returns.

Is Chemo Pharma Lab overvalued or undervalued?

As of April 25, 2023, Chemo Pharma Lab is considered a risky investment due to its overvaluation indicated by a PE ratio of 19.25, negative EV to EBIT and EBITDA, and a low ROCE of -3.04%, especially when compared to its peers, and it has recently underperformed the market with a one-week return of -9.53%.

As of 25 April 2023, Chemo Pharma Lab's valuation grade has moved from does not qualify to risky, indicating a shift in its perceived investment quality. The company appears to be overvalued based on its current metrics, particularly with a PE ratio of 19.25 and a negative EV to EBIT and EV to EBITDA of -12.50. Additionally, the ROCE stands at -3.04%, which raises concerns about its operational efficiency.<BR><BR>In comparison to its peers, Chemo Pharma Lab's valuation is notably less attractive. For instance, Altius Telecom, categorized as very attractive, has a PE ratio of 52.97, while other peers like Embassy Off.REIT and Inventurus Knowl are deemed very expensive with PE ratios of 23.06 and 56.63, respectively. Chemo Pharma Lab's stock has underperformed recently, with a one-week return of -9.53% compared to a 1.41% gain in the Sensex, further supporting the notion that it is currently overvalued.

What is the technical trend for Chemo Pharma Lab?

As of March 17, 2025, Chemo Pharma Lab's technical trend is bullish, supported by strong upward momentum from the MACD and KST, despite mixed signals from other indicators.

As of 17 March 2025, the technical trend for Chemo Pharma Lab has changed from mildly bullish to bullish. The weekly and monthly MACD indicators are both bullish, supporting a strong upward momentum. The KST also confirms this bullish stance on both time frames. While the RSI shows no signal, the Bollinger Bands indicate a mildly bullish trend on both weekly and monthly charts. The daily moving averages are mildly bullish, suggesting some short-term strength. Overall, the current technical stance is bullish with a strong momentum indicated by the MACD and KST, despite some mixed signals from other indicators.

Who are in the management team of Chemo Pharma Lab?

As of March 2023, the management team of Chemo Pharma Lab includes Ashok Somani (Executive Director & CFO), Toby Antony (Independent Director), Shanta Somani (Non-Executive Director), Mathura Prasad Sharma (Independent Director), Bhavin Sheth (Director & CEO), Nandkumar Pareek (Independent Director), and Unnatti Jain (Company Secretary & Compliance Officer). These individuals oversee the company's governance and operations.

As of March 2023, the management team of Chemo Pharma Lab includes the following individuals:<BR><BR>1. Ashok Somani - Executive Director & CFO<BR>2. Toby Antony - Independent Director<BR>3. Shanta Somani - Non Executive Director<BR>4. Mathura Prasad Sharma - Independent Director<BR>5. Bhavin Sheth - Director & Chief Executive Officer<BR>6. Nandkumar Pareek - Independent Director<BR>7. Unnatti Jain - Company Secretary & Compliance Officer<BR><BR>These members play various roles within the company, contributing to its governance and operational management.

What does Chemo Pharma Lab do?

Chemo Pharma Laboratories Ltd is a micro-cap company in the Pharmaceuticals & Biotechnology sector, established in 1942, currently reporting a net profit of -3 Cr for Q1 2025 and a market cap of INR 17 Cr. Key financial metrics include a P/E of 18.00 and a debt-equity ratio of -0.49.

Overview:<BR>Chemo Pharma Laboratories Ltd is a micro-cap company operating in the Pharmaceuticals & Biotechnology industry, focusing on pharmaceuticals and bulk drugs.<BR><BR>History:<BR>Established in August 1942, Chemo Pharma Laboratories has undergone significant changes, including the disposal of its business due to increased competition. The latest financial report indicates a net profit of -3 Cr for the quarter ending March 2025.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: -3 Cr (Quarterly Results - Mar 2025)<BR>Market-cap value: INR 17 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 18.00<BR>Industry P/E: 32<BR>Dividend Yield: 0.00%<BR>Debt-Equity: -0.49<BR>Return on Equity: 2.56%<BR>Price-to-Book: 1.34<BR><BR>Contact Details:<BR>Address: 5 Kumud Apartment CHS Ltd, Karnik Road Chikan Ghar Kalyan Thane Maharashtra : 421301<BR>Phone: 91-022-22078381/22078382<BR>Email: chemopharmalab@gmail.com<BR>Website: http://www.thechemopharmalaboratoriesltd.com

Who are the top shareholders of the Chemo Pharma Lab?

The top shareholders of Chemo Pharma Lab are Citric India Ltd with 24.63% and Shree Consultation And Services Pvt Ltd with 3.63%. Individual investors own a combined 65.29%, with no mutual funds or foreign institutional investors currently holding shares.

The top shareholders of Chemo Pharma Lab include Citric India Ltd, which holds the highest promoter stake at 24.63%. Additionally, Shree Consultation And Services Pvt Ltd is the highest public shareholder with a holding of 3.63%. Individual investors collectively own 65.29% of the company. There are no mutual funds or foreign institutional investors currently holding shares in Chemo Pharma Lab.

How big is Chemo Pharma Lab?

As of 24th July, Chemo Pharma Laboratories Ltd has a market capitalization of 19.00 Cr, categorizing it as a Micro Cap company, with reported Net Sales of 0.00 Cr and a Net Profit of 0.35 Cr in the latest four quarters.

As of 24th July, Chemo Pharma Laboratories Ltd has a market capitalization of 19.00 Cr, which categorizes it as a Micro Cap company.<BR><BR>In the latest four quarters, Chemo Pharma Laboratories Ltd reported Net Sales of 0.00 Cr and a Net Profit of 0.35 Cr.<BR><BR>The latest annual period for the balance sheet is March 2016, with Shareholder's Funds amounting to 3.67 Cr and Total Assets valued at 3.87 Cr.

When is the next results date for Starsource Multi?

The next results date for Starsource Multi is 13 November 2025.

The next results date for Starsource Multi is scheduled for 13 November 2025.

How has been the historical performance of Starsource Multi?

The historical performance of Starsource Multi for the year ending March 2016 was poor, with total operating income of 0.49 Cr, a loss before tax of -1.35 Cr, and a negative EPS of -9.66, indicating significant financial challenges. The company had total liabilities of 3.87 Cr against shareholder's funds of 3.67 Cr, reflecting a precarious financial position.

Answer:<BR>The historical performance of Starsource Multi for the year ending March 2016 shows a challenging financial situation with negative profitability and limited operational activity.<BR><BR>Breakdown:<BR>In March 2016, Starsource Multi reported total operating income of 0.49 Cr, derived primarily from other operating income, as net sales were recorded at 0.00 Cr. The total expenditure, excluding depreciation, amounted to 1.84 Cr, leading to an operating profit (PBDIT) of -1.35 Cr. Consequently, the profit before tax also stood at -1.35 Cr, resulting in a profit after tax of -1.45 Cr. The company had a negative earnings per share (EPS) of -9.66 and an operating profit margin of -273.78%. On the balance sheet, shareholder's funds totaled 3.67 Cr, with total liabilities at 3.87 Cr, indicating a precarious financial position. The cash flow from operating activities was -2.09 Cr, while cash flow from investing activities showed a positive inflow of 2.15 Cr, leading to a net cash inflow of 0.06 Cr by the end of the period, with closing cash and cash equivalents at 0.44 Cr.

Which are the latest news on Starsource Multi?

Why is Starsource Multi falling/rising?

As of 03-Dec, the stock price of Starsource Multitrade Ltd is at 110.00, down 2.74%. This decline is due to volatility during trading, underperformance against its sector, and a bearish trend indicated by moving averages.

As of 03-Dec, the stock price of Starsource Multitrade Ltd is currently at 110.00, reflecting a decrease of 3.1 points or 2.74%. This decline can be attributed to several factors observed in the stock's performance today. Although the stock opened with a gain of 2.48% and reached an intraday high of Rs 115.9, it subsequently fell to its day's low of Rs 110, indicating significant volatility within the trading session.<BR><BR>Moreover, the stock has underperformed its sector by 2.04% today, which may have contributed to the downward pressure on its price. While there has been a rise in investor participation, with a delivery volume increase of 38.32% compared to the 5-day average, the weighted average price suggests that more volume was traded closer to the low price, indicating a lack of strong buying interest at higher levels.<BR><BR>In terms of moving averages, the stock is currently higher than its 5-day moving average but lower than the 20-day, 50-day, 100-day, and 200-day moving averages, which may signal a bearish trend in the short to medium term. Overall, these factors combined have led to the observed decline in the stock price of Starsource Multitrade Ltd.